Inflammatory Bowel Diseases最新文献_第2页

Reply to "Improving Brain-Gut Studies in Crohn's Disease: Methodological Considerations".

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-13 DOI: 10.1093/ibd/izaf051

Anne Kerstin Thomann, Robert Christian Wolf

引用次数: 0

Improving Brain-Gut Studies in Crohn's Disease: Methodological Considerations.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-13 DOI: 10.1093/ibd/izaf055

Jinyu Wu, Wen Wang

引用次数: 0

Utilization of Super-Resolution Contrast-Enhanced Ultrasonography in Diagnosing Intestinal Behçet's Disease With Enterovesical Fistula.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-13 DOI: 10.1093/ibd/izaf040

Saidaitiguli Aihemaiti, Zi-Yin Ye, Ren Mao, Yu-Jun Chen

引用次数: 0

Total Proctocolectomy Versus Subtotal/Total Colectomy for Neoplasia in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-13 DOI: 10.1093/ibd/izaf003

Katie Dunleavy, Laura Raffals

引用次数: 0

Reply: Opioids Intertwined With Psychology: Hidden Effects in the Treatment of Patients With IBD.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-12 DOI: 10.1093/ibd/izae305

Christy Riggott, Keeley M Fairbrass, Christian P Selinger, David J Gracie, Alexander C Ford

引用次数: 0

A Comprehensive Perspective on Primary Sclerosing Cholangitis Research: Multidimensional Analysis From Literature Review to Patient Quality of Life.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-12 DOI: 10.1093/ibd/izae311

Yunxia Zhang, Taifu You, Sheng Li

引用次数: 0

Opioids Intertwined With Psychology: Hidden Effects in the Treatment of Patients With IBD.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-12 DOI: 10.1093/ibd/izae300

Yunxia Zhang, Taifu You, Sheng Li

引用次数: 0

Altered Bile Acids and Pouch Microbiota Composition in Patients With Chronic Pouchitis.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-12 DOI: 10.1093/ibd/izaf005

Katie Dunleavy, Michael Camilleri, Laura Raffals

引用次数: 0

Characterization of the Regulatory Landscape in Crohn's Disease Reveals microRNA-Associated Alterations that Shape Anti-TNF Response.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-11 DOI: 10.1093/ibd/izaf029

Luis Cervera-Seco, Montse Baldán-Martín, Samuel Fernández-Tomé, Lorena Ortega Moreno, Juan J Lozano, Ana M Aransay, María Chaparro, Javier P Gisbert, Urko M Marigorta

{"title":"Characterization of the Regulatory Landscape in Crohn's Disease Reveals microRNA-Associated Alterations that Shape Anti-TNF Response.","authors":"Luis Cervera-Seco, Montse Baldán-Martín, Samuel Fernández-Tomé, Lorena Ortega Moreno, Juan J Lozano, Ana M Aransay, María Chaparro, Javier P Gisbert, Urko M Marigorta","doi":"10.1093/ibd/izaf029","DOIUrl":"https://doi.org/10.1093/ibd/izaf029","url":null,"abstract":"Background: MicroRNAs (miRNAs) play a key role in regulating gene expression in Crohn's disease (CD). Although several studies have identified miRNAs with biomarker potential, an exhaustive characterization of the miRNAome in CD is still lacking. We performed the largest miRNA profiling effort to date to analyze miRNA variability across intestinal tissues, disease activity status, and infliximab treatment in CD.Methods: We generated 119 transcriptomic profiles from the terminal ileum and left colon biopsies of 30 individuals (10 with active CD, 10 with quiescent CD, and 10 healthy controls). Half of the samples were cultured ex vivo with infliximab, and the remaining half with basal medium. Using variance analyses and linear mixed differential expression models, we explored the determinants of miRNAome variability in CD. We also generated infliximab response signatures to identify candidates and examine interactions between miRNAs and the coding transcriptome.Results: Tissue location, and patient-specific effects, were the main factors in miRNA variability in CD, with some differentially expressed miRNAs involved in epithelial-mesenchymal transition (miR-200s, miR-429). We identified 9 miRNAs with treatment-responsive behaviour, particularly to the terminal ileum of active CD cases. Although the changes observed in active CD cases suggest that many alterations are not offset by infliximab incubation, we described 13 miRNAs-mRNA pairs with potential involvement in the anti-tumor necrosis factor (TNF) treatment, 7 of which have been already validated.Conclusions: A comprehensive miRNA profiling revealed significant intestinal tissue-specific variability and identified key alterations in the miRNA-mRNA interactome that might be involved in therapeutic response to anti-TNF in CD.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-11 DOI: 10.1093/ibd/izaf043

Katie A Dunleavy, Chad R Rypstra, Irene Busciglio, Deborah Eckert, Michael Ryks, Ellie Omerdic, Victor G Chedid, Laura E Raffals, Michael Camilleri

{"title":"Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission.","authors":"Katie A Dunleavy, Chad R Rypstra, Irene Busciglio, Deborah Eckert, Michael Ryks, Ellie Omerdic, Victor G Chedid, Laura E Raffals, Michael Camilleri","doi":"10.1093/ibd/izaf043","DOIUrl":"https://doi.org/10.1093/ibd/izaf043","url":null,"abstract":"Background and aims: Inflammatory bowel disease (IBD) is associated with altered mucus and increased intestinal permeability (IP). Prior reports on permeability in IBD typically used lactulose-to-mannitol ratio (LMR). Food contamination with 12C-mannitol is a significant potential confounder in IP assessment. We aimed to compare small intestinal (SI) and colonic (COL) permeability in IBD, both active (ACT) and in remission (REM), to normal healthy volunteers (NHV).Methods: Inflammatory bowel disease activity was based on Simple Endoscopic Score for Crohn's Disease (SES-CD) and Mayo endoscopy score for ulcerative colitis (UC). We performed 24-hour IP test using 100 mg 13C-mannitol and 1000 mg lactulose with urine collected during 0-2, 2-8, and 8-24 hours. The primary endpoint was mg excretion of 13C-mannitol and lactulose during 2-24 hours reflecting SI and COL permeability.Results: Among 17 CD patients, 7 were ACT (SES-CD >6), and 10 REM (SES-CD 0-2). Among 20 UC patients, 10 had ACT (Mayo score 2-3), and 10 REM (Mayo score 0-1). Urinary excretions over 2-24 hours were higher for IBD than NHV: 13C-mannitol (13.8 [IQR 8.8, 18.7] NHV; 18.4 [15.6, 29.9] REM; 19.7 [13.8, 23.6] ACT, P = .003) and lactulose (1.8 [1.3, 3.1] NHV; 3.6 [2.0, 5.0] REM; 3.5 [2.0, 6.6] ACT, P = .006). There was no difference between ACT and REM for any timed urine collection. LMR at 2-24 hours (or 2-8 and 8-24 hours) were not statistically significant between the 3 groups (0.014 [0.010, 0.021] NHV; 0.016 [0.010, 0.023] REM; 0.016 [0.012, 0.038] ACT, P = .237).Conclusions: Intestinal permeability is increased in IBD using validated in vivo assay relative to NHV; increased IP in IBD persists during remission.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0